Kiniksa Pharmaceuticals International (KNSA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is KNSA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Aberdeen Group plc decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 13.9% during the third quarter, according to the company in its most recent disclosure with the Securiti…

Fisher Asset Management LLC trimmed its position in Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 18.7% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 323,80…

LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in Lon…

AlphaCentric Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during a recent quarter, according to its most recent 13F filing with the SEC. The firm bought 7,987 …

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.…

Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the dru…

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript…

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.…

– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Pha…

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern T…

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday. The company traded as high as $83.78 and last traded at $83.17, with a vol…

B. Riley Wealth Advisors Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during the third quarter, according to the company in its most recent Form 13F filing with the …

Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare th…

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat reports. …

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.…

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conferenc…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

